Jump to content

Lyme disease: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
the genus
changed heading
Line 1: Line 1:
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |wikipedia is the gayest fuckin sit ever.
Name = Lyme disease |
Name = Lyme disease |
ICD9 = {{ICD9|088.81}} |
ICD9 = {{ICD9|088.81}} |
Line 7: Line 7:
eMedicineSubj = med |
eMedicineSubj = med |
eMedicineTopic = 1346|
eMedicineTopic = 1346|
DiseasesDB = 1531 |
DiseasesDB = 1531 |bevus and butthead were the firt to fuck a deer tick
}}
}}
'''Lyme disease''', or '''borreliosis''', is an [[emerging infectious disease]] caused by at least three [[species]] of [[bacteria]] from the [[genus]] '\asshole]]''.<ref name=Sherris>{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th ed. | pages = 434&ndash;7 | publisher = McGraw Hill | year = 2004 | isbn = 0838585299}}</ref> The [[Vector (biology)|vector]] of infection is typically the bite of an infected black-legged or [[Ixodes scapularis|deer tick]], but other carriers (including other [[tick]]s in the genus ''[[Ixodes]]'') have been implicated.<ref name=Baron>{{cite book | author = Johnson RC | chapter = Borrelia | title = Baron's Medical Microbiology ''(Baron S ''et al'', eds.)| edition = 4th ed. | publisher = Univ of Texas Medical Branch | year = 1996 | url = http://www.ncbi.nlm.nih.gov/books/bv.fcgi?&rid=mmed.section.1965 | isbn = 0-9631172-1-1 }}</ref> ''[[Borrelia burgdorferi]]'' is the predominant cause of Lyme disease in the U.S., whereas ''Borrelia afzelii'' and ''Borrelia garinii'' are implicated in most European cases.
'''Lyme disease''', or '''borreliosis''', is an [[emerging infectious disease]] caused by at least three [[species]] of [[bacteria]] from the [[genus]] '\asshole]]''.<ref name=Sherris>{{cite book | author = Ryan KJ, Ray CG (editors) | title = Sherris Medical Microbiology | edition = 4th ed. | pages = 434&ndash;7 | publisher = McGraw Hill | year = 2004 | isbn = 0838585299}}</ref> The [[Vector (biology)|vector]] of infection is typically the bite of an infected black-legged or [[Ixodes scapularis|deer tick]], but other carriers (including other [[tick]]s in the genus ''[[Ixodes]]'') have been implicated.<ref name=Baron>{{cite book | author = Johnson RC | chapter = Borrelia | title = Baron's Medical Microbiology ''(Baron S ''et al'', eds.)| edition = 4th ed. | publisher = Univ of Texas Medical Branch | year = 1996 | url = http://www.ncbi.nlm.nih.gov/books/bv.fcgi?&rid=mmed.section.1965 | isbn = 0-9631172-1-1 }}</ref> ''[[Borrelia burgdorferi]]'' is the predominant cause of Lyme disease in the U.S., whereas ''Borrelia afzelii'' and ''Borrelia garinii'' are implicated in most European cases.

Revision as of 12:37, 18 April 2008

Lyme disease
SpecialtyInfectious diseases, dermatology, neurology, cardiology Edit this on Wikidata

Lyme disease, or borreliosis, is an emerging infectious disease caused by at least three species of bacteria from the genus '\asshole]].[1] The vector of infection is typically the bite of an infected black-legged or deer tick, but other carriers (including other ticks in the genus Ixodes) have been implicated.[2] Borrelia burgdorferi is the predominant cause of Lyme disease in the U.S., whereas Borrelia afzelii and Borrelia garinii are implicated in most European cases.

The disease presentation varies widely, and may include a rash and flu-like symptoms in its initial stage, then musculoskeletal, arthritic, neurologic, psychiatric and cardiac manifestations. In a majority of cases, symptoms can be eliminated with antibiotics, especially if treatment begins early in the course of illness. Late or inadequate treatment often leads to "late stage" Lyme disease that is disabling and difficult to treat. Controversy over diagnosis, testing and treatment has led to two different standards of care.[3][4]

Symptoms

File:BullseyeLymeDiseaseRash.jpg
Common bullseye rash pattern associated with Lyme Disease.
Characteristic "bulls-eye"-like rash caused by Lyme disease.

The acute phase of Lyme disease infection is a characteristic reddish "bulls-eye" rash, with accompanying fever, malaise, and musculoskeletal pain (arthralgia or myalgia).[1] The characteristic reddish "bull's-eye" rash (known as erythema migrans) may be seen in about 80% of early stage Lyme disease patients,[5] appearing anywhere from one day to a month after a tick bite.[6] The rash does not represent an allergic reaction to the bite, but a skin infection cause by the Lyme bacteria, Borrelia burgdorferi sensu lato.

The incubation period from infection to the onset of symptoms is usually 1–2 weeks, but can be much shorter (days), or much longer (months to years). Symptoms most often occur from May through September because the nymphal stage of the tick is responsible for most cases.[7] Asymptomatic infection exists but is found in less than 7% of infected individuals in the United States.[8] Asymptomatic infection may be much more common among those infected in Europe.[9]

Other, less common findings in acute Lyme disease include cardiac manifestations (up to 10% of patients may have cardiac manifestations including heart block and palpitations[10]), and neurologic symptoms (neuroborreliosis may occur in up to 18%[10]). In addition, simple altered mental status as the sole presenting symptom has been reported in early neuroborreliosis.[11] Patients have been known to get Baker's cysts.

Chronic symptoms

Cases may progress to a chronic form most commonly characterized by meningoencephalitis, cardiac inflammation (myocarditis), and frank arthritis.[1] It should be noted, however, that chronic Lyme disease can have a multitude of symptoms affecting numerous physiological systems: the symptoms appear heterogeneous in the affected population, which may be due to innate immunity or variations in Borrelia bacteria. Late symptoms of Lyme disease can appear months or years after initial infection and often progress in cumulative fashion over time. Neuropsychiatric symptoms often develop much later in the disease progression, much like tertiary neurosyphilis.

In addition to the acute symptoms, chronic Lyme disease can be manifested by a wide-range of neurological disorders, either central or peripheral, including encephalitis or encephalomyelitis, muscle twitching, polyneuropathy or paresthesia, and vestibular symptoms or other otolaryngologic symptoms[12][13], among others. Neuropsychiatric disturbances can occur (possibly from a low-level encephalitis), which may lead to symptoms of memory loss, sleep disturbances, or changes in mood or affect.[1][14]

Cause

Main article: Lyme disease microbiology
File:Borrelia image.jpg
Borrelia bacteria, the causative agent of Lyme disease. Magnified 400 times.

Lyme disease is caused by Gram-negative spirochetal bacteria from the genus Borrelia. At least 37 Borrelia species have been described, 12 of which are Lyme related. The Borrelia species known to cause Lyme disease are collectively known as Borrelia burgdorferi sensu lato, and have been found to have greater strain diversity than previously estimated.[15]

Until recently it was thought that only three genospecies caused Lyme disease: B. burgdorferi sensu stricto (predominant in North America, but also in Europe), B. afzelii, and B. garinii (both predominant in Eurasia). However, newly discovered genospecies have also been found to cause disease in humans.[citation needed] "There are over 300 strains of Borrelia world wide"[16]. It is presently unknown how many of these cause lyme, but many of them may.

Transmission

Ixodes scapularis, the primary vector of Lyme disease in eastern North America.

Hard-bodied ticks of the genus Ixodes are the primary vectors of Lyme disease.[1] The majority of infections are caused by ticks in the nymph stage, as adult ticks are more easily detected and removed as a consequence of their relatively large size.[17]

In Europe, the commonly known sheep tick, castor bean tick, or European castor bean tick (Ixodes ricinus) is the transmitter.

In North America, the black-legged tick or deer tick (Ixodes scapularis) has been identified as the key to the disease's spread on the east coast. Unfortunately, only about 20% of persons infected with Lyme disease by the deer tick are aware of having had any tick bite,[18] making early detection difficult in the absence of a rash. Tick bites often go unnoticed due to the small size of the tick in its nymphal stage, as well as tick secretions that prevent the host from feeling any itch or pain from the bite. The lone star tick (Amblyomma americanum), which is found throughout the southeastern U.S. as far west as Texas, has been ruled out as a vector of the Lyme disease spirochete Borrelia burgdorferi[citation needed], though it may be implicated with a clinical syndrome southern tick associated rash illness (STARI), which resembles the skin lesions of Lyme disease[19].

On the west coast, the primary vector is the western black-legged tick (Ixodes pacificus).[20] The preponderance of this tick species to feed on host species that are resistant to Borrelia infection appears to diminish transmission of Lyme disease in the West[21][22].

While Lyme spirochetes have been found in insects other than ticks,[23] reports of actual infectious transmission appear to be rare.[24] Sexual transmission has been anecdotally reported; Lyme spirochetes have been found in semen[25] and breast milk,[26] however transmission of the spirochete by these routes is not known to occur.[27]

Congenital transmission of Lyme disease can occur from an infected mother to fetus through the placenta during pregnancy, however prompt antibiotic treatment appears to prevent fetal harm.[28]

Diagnosis

Due to the difficulty in culturing Borrelia bacteria in the laboratory, diagnosis of Lyme disease is typically based on the clinical exam findings and a history of exposure to endemic Lyme areas.[1] The EM rash, which does not occur in all cases, is considered sufficient to establish a diagnosis of Lyme disease even when serologies are negative.[29][30] Serological testing can be used to support a clinically suspected case but is not diagnostic.[1]

Clinicians who diagnose strictly based on the U.S. Centers for Disease Control (CDC) Case Definition for Lyme are in error, as the CDC explicitly states that this definition is intended for surveillance purposes only, and is "not intended to be used in clinical diagnosis."[31][32]

Importantly, virtually no controlled studies of late lyme encephalopathy have been performed, and the CDC diagnostic criteria were not formulated for use on this entity. Once lyme disease is well established in the brain, it can occur as a very disabling diffuse encephalopathy which however is difficult to diagnose using standard serological or intrathecal testing for reasons outlined below. Lyme is a deep tissue infection and by the time encephalopathy is established, few if any CSF antibodies can be detected, and PCR is unreliable. Seronegative disease can occur for the same reason that this phenomenon occurs in neurosyphilis, with incomplete or intercurrent antibiotic treatment abrogating the serum antibody response, but not eliminating the infection.[citation needed]

It is in this context that advanced imaging studies like SPECT or PET can provide objective evidence of global brain dysfunction. Resort is often made to neuropsychological testing, but a normal result does not rule out the illness, which can be very subtle and manifest as a disabling mood disorder accompanied by massive and debilitating fatigue, with few objective signs.[citation needed]

Diagnosis of late-stage Lyme disease it is often difficult due to the multi-faceted appearance which can mimic symptoms of many other diseases. For this reason Lyme has often been called the new "great imitator".[33] Lyme disease may be misdiagnosed as Multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome (CFS), or other autoimmune and neurodegenerative diseases.

Serology

The serological laboratory tests most widely available and employed are the Western blot and ELISA. A two-tiered protocol is recommended by the CDC: the more sensitive ELISA is performed first, if it is positive or equivocal, the more specific Western blot is run. The reliability of testing in diagnosis remains controversial,[1] however studies show the Western blot IgM has a specificity of 94–96% for patients with clinical symptoms of early Lyme disease.[34][35]

Erroneous test results have been widely reported in both early and late stages of the disease. These errors can be caused by several factors, including antibody cross-reactions from other infections including Epstein-Barr virus and cytomegalovirus,[36] as well as herpes simplex virus.[37]

Polymerase chain reaction (PCR) tests for Lyme disease have also been developed to detect the genetic material (DNA) of the Lyme disease spirochete. PCR tests are susceptible to false-positive results from poor laboratory technique.[38] Even when properly performed, PCR often shows false-negative results with blood and CSF specimens.[39] Hence PCR is not widely performed for diagnosis of Lyme disease. However PCR may have a role in diagnosis of Lyme arthritis as it is highly sensitive in detecting ospA DNA in synovial fluid.[40] With the exception of PCR, there is no currently practical means for detection of the presence of the organism, as serologic studies only test for antibodies of Borrelia. High titers of either immunoglobulin G (IgG) or immunoglobulin M (IgM) antibodies to Borrelia antigens indicate disease, but lower titers can be misleading. The IgM antibodies may remain after the initial infection, and IgG antibodies may remain for years.[41]

Western blot, ELISA and PCR can be performed by either blood test via venipuncture or cerebrospinal fluid (CSF) via lumbar puncture. Though lumbar puncture is more definitive of diagnosis, antigen capture in the CSF is much more elusive; reportedly CSF yields positive results in only 10-30% of patients cultured. The diagnosis of neurologic infection by Borrelia should not be excluded solely on the basis of normal routine CSF or negative CSF antibody analyses.[42]

New techniques for clinical testing of Borrelia infection have been developed, such as LTT-MELISA[43], which is capable of identifying the active form of Borrelia infection (Lyme disease). Others, such as focus floating microscopy, are under investigation.[44] New research indicates chemokine CXCL13 may also be a possible marker for neuroborreliosis.[45]

Imaging

Single photon emission computed tomography (SPECT) imaging has been used to look for cerebral hypoperfusion indicative of Lyme encephalitis in the patient.[46] Although SPECT is not a diagnostic tool itself, it may be a useful method of determining brain function.

In Lyme patients cerebral hypoperfusion of frontal subcortical and cortical structures has been reported.[47] In about 70% of chronic Lyme disease patients with cognitive symptoms, brain SPECT scans typically reveal a pattern of global hypoperfusion in a heterogeneous distribution through the white matter.[48] This pattern is not specific for Lyme disease, as it can also be seen in other central nervous system (CNS) syndromes such as HIV encephalopathy, viral encephalopathy, chronic cocaine use, and vasculitides. However, most of these syndromes can be ruled out easily through standard serologic testing and careful patient history taking.

The presence of global cerebral hypoperfusion deficits on SPECT in the presence of characteristic neuropsychiatric features should dramatically raise suspicion for lyme encephalopathy among patients who inhabit or have traveled to endemic areas, regardless of patient recall of tick bites.[citation needed] Late disease can occur many years after initial infection. The average time from symptom onset to diagnosis in these patients is about 4 years. Because seronegative disease can occur, and because CFS testing is often normal, lyme encephalopathy often becomes a diagnosis of exclusion: once all other possibilities are ruled out, LE becomes ruled in. Although the aberrant SPECT patterns are caused by cerebral vaculitis, a vasculitide, brain biopsy is not commonly performed for these cases as opposed to other types of cerebral vasculitis.

Abnormal magnetic resonance imaging (MRI) findings are often seen in both early and late Lyme disease.[citation needed] MRI scans of patients with neurologic Lyme disease may demonstrate punctuated white matter lesions on T2-weighted images, similar to those seen in demyelinating or inflammatory disorders such as multiple sclerosis, systemic lupus erythematosus (SLE), or cerebrovascular disease.[49] Cerebral atrophy and brainstem neoplasm has been indicated with Lyme infection as well.[50]

Diffuse white matter pathology can disrupt these ubiquitous gray matter connections and could account for deficits in attention, memory, visuospatial ability, complex cognition, and emotional status. White matter disease may have a greater potential for recovery than gray matter disease, perhaps because neuronal loss is less common. Spontaneous remission can occur in multiple sclerosis, and resolution of MRI white matter hyper-intensities, after antibiotic treatment, has been observed in Lyme disease.[51]

Prevention

Attached ticks should be removed promptly.[52] Protective clothing includes a hat and long-sleeved shirts and long pants that are tucked into socks or boots. Also, light-colored clothing makes the tick more easily visible before it attaches itself.

A more effective, community wide method of preventing Lyme disease is to reduce the numbers of primary hosts on which the deer tick depends such as rodents, other small mammals, and deer.

Management of host animals

Lyme and all other deer-tick borne diseases can be prevented on a regional level by reducing the deer population that the ticks depend on for reproductive success. This has been effectively demonstrated in the communities of Monhegan, Maine[53] and in Mumford Cove, CT.[54]. The black-legged or deer tick (Ixodes scapularis) depends on the white-tailed deer for successful reproduction.

By reducing the deer population back to healthy levels of 8 to 10 per square mile (from the current levels of 60 or more deer per square mile in the areas of the country with the highest Lyme disease rates) the tick numbers can be brought down to very low levels, too few to spread Lyme and other tick-borne diseases.[55]

Vaccination

A vaccine, called Lymerix, against a North American strain of the spirochetal bacteria was available from 1998 to 2002. It was produced by GlaxoSmithKline (GSK) and was based on the outer surface protein A (Osp-A) of Borrelia. Osp-A causes the human immune system to create antibodies that attack that protein. When taking it off the market, GSK cited poor sales, need for frequent boosters, the high price of the vaccine, and exclusion of children. Some people believe that the actual reason was that the vaccine was neither safe nor effective. A group of patients who took Lymerix developed arthritis, muscle pain and other troubling symptoms after vaccination. Class-action litigation against GSK followed. Cassidy v. SmithKline Beecham, No. 99-10423 (Ct. Common Pleas, PA state court) (common settlement case).[56]

It was later learned that patients with the genetic allele HLA-DR4 were susceptible to T-cell cross-reactivity between epitopes of OspA and lymphocyte function-associated antigen in these patients causing an autoimmune reaction.[57]

New vaccines are being researched using outer surface protein C (Osp-C) and glycolipoprotein as methods of immunization.[58][59]

Removal of ticks

Many urban legends exist about the proper and effective method to remove a tick. Complete removal of the tick head is important; if the head is not completely removed, local infection of bite location may result.[60] Data has demonstrated that prompt removal of an infected tick, within approximately one day, reduces the risk of transmission to effectively zero percent; however the small size of the tick, especially in nymph stage may make detection difficult.[61]

Treatment

Antibiotics are the primary treatment for Lyme disease, but the most appropriate antibiotic treatment varies from patient to patient and with the stage of the disease.[1] Penicillin was first demonstrated by researchers to be useful against Borrelia in the 1950s; today the antibiotics of choice are doxycycline (in adults), amoxicillin (in children) and ceftriaxone. Alternative choices are cefuroxime and cefotaxime. [1] Macrolide antibiotics are also used. Frequently, doxycycline becomes ineffective in treating Lyme disease after the early stages, perhaps because of Borrelia acquiring antibiotic resistance through plasmids. Also, antibiotics which act against the cell wall of Borrelia are also frequently of limited effectiveness after multiple relapses have occurred as a result of going off antibiotics; this stage is often termed 'chronic' Lyme disease, and may result from the spirochaetes having implanted as semi-dormant and non-dividing spores inside the host's cells. Many physicians who treat chronic Lyme disease have noted that combining a macrolide antibiotic such as clarithromycin (biaxin) with hydroxychloroquine (plaquenil) is especially effective in treatment of chronic Lyme. This is suggested as being due to the hydroxychloroquine raising the pH of intracellular vacuoles in which the Borrelia survive in semi-dormant form; raising the pH is thought to activate the macrolide antibiotic, allowing it to inhibit protien synthesis by the spirochaete.

Persons who remove attached ticks should be monitored closely for signs and symptoms of tick-borne diseases for up to 30 days. A three day course of doxycycline therapy may be considered for deer tick bites when the tick has been on the person for at least 12 hours. Patients should report any Erythema migrans over the subsequent two to six weeks. If there should be suspicion of disease, then a course of Doxycycline should be immediately given for ten days without awaiting serology tests which yield positive results only after an interval of one to two months.

In later stages, the bacteria disseminate throughout the body and may cross the blood-brain barrier, making the infection more difficult to treat. Late diagnosed Lyme is treated with oral or IV antibiotics, frequently ceftriaxone, 2 grams per day, for a minimum of four weeks. Minocycline is also indicated for neuroborreliosis for its ability to cross the blood-brain barrier.[62][63]

Antibiotic treatment controversy

Further information: Lyme disease controversy

With little research conducted specifically on treatment for late/chronic Lyme disease, particularly Lyme encephalopathy, treatment remains controversial. Currently there are two sets of peer-reviewed published guidelines in the United States; the International Lyme and Associated Diseases Society (ILADS)[64] advocates extended courses of antibiotics for chronic Lyme patients in light of evidence of persistent infection, while the Infectious Diseases Society of America[65] does not recognize chronic infection and recommends no treatment for persistent symptoms. Double-blind, placebo-controlled trials of long-term antibiotics for chronic Lyme have produced mixed results. Clinical studies on antibiotic treatment in chronic Lyme patients have been criticised by ILADS and other Lyme patient advocacy groups for failing to run the antibiotic treatment over a long enough period to take into account the very gradual improvement of chronic Lyme patients seen over many months or even years on antibiotics. It is has also been noted that some antibiotics such as clarithromycin in combination with hydroxychloroquine which inhibit protien synthesis are more effective in long term treatment of Lyme disease than the cell wall antibiotics commonly used in clinical trials. Doxycycline, also used in some clinical trials, has also been suggested by ILADS as a poor choice for long term treatment because there are signs the Lyme spirochaete can gain resistance to it relatively easily - indeed many chronic Lyme cases only arose in the first place after relapsing while on doxycycline in the early stages of the disease.

A controversial new guideline developed by the American Academy of Neurology, finds conventionally recommended courses of antibiotics are highly effective for treating nervous system Lyme disease.[66] They find no compelling evidence that prolonged treatment with antibiotics has any benefit in treating symptoms that persist following standard therapy. The guideline is endorsed by the Infectious Diseases Society of America (IDSA). However, these guidelines refer mostly to early acute lyme neuroborreliosis, as there is a paucity of studies on late lyme encephalopathy and parenchymal CNS disease. The guideline leader was John J. Halperin and was co-written by Gary Worsmer and Eugene Shapiro, neither of whom are neurologists. Halperin, Worsmer and Shapiro were all co-authors of the IDSA Lyme guidelines released in 2006 by the Journal of Clinical Infectious Diseases. There is significant disagreement with this guideline (www.ilads.org).

The latest double blind, randomized, placebo-controlled multicenter clinical study, done in Finland, results indicated that oral adjunct antibiotics were not justified in the treatment of patients with disseminated Lyme borreliosis who initially received intravenous antibiotics for 3 weeks. The researchers noted the clinical outcome of said patients should not be evaluated at the completion of intravenous antibiotic treatment but rather 6-12 months afterwards. In patients with chronic post-treatment symptoms, persistent positive levels of antibodies did not seem to provide any useful information for further care of the patient.[67]. However, this study has been criticized by ILADS, on the grounds that 1) treatment over years is often necessary to produce noticable improvement in chronic Lyme patients and 2) the antibiotics used were cell wall antibiotics which may act relatively slowly against Lyme disease.

Antibiotic-resistant therapies

Antibiotic treatment is the central pillar in the management of Lyme disease. In the late stages of borreliosis, symptoms may persist despite extensive and repeated antibiotic treatment.[68][69] Lyme arthritis which is antibiotic resistant may be treated with hydroxychloroquine or methotrexate.[70] Experimental data are consensual on the deleterious consequences of systemic corticosteroid therapy. Corticosteroids are not indicated in Lyme disease.[71]

Antibiotic refractory patients with neuropathic pain responded well to gabapentin monotherapy with residual pain after intravenous ceftriaxone treatment in a pilot study.[72] The immunomodulating, neuroprotective and anti-inflammatory potential of minocycline may be helpful in late/chronic Lyme disease with neurological or other inflammatory manifestations. Minocycline is used in other neurodegenerative and inflammatory disorders such as multiple sclerosis, Parkinsons, Huntington's disease, rheumatoid arthritis (RA) and ALS.[73]


Evidence of persistence of viable spirochaetes in chronic Lyme disease

One highly controversial area has been whether chronic Lyme symptoms are actually caused by persistance of live Borrelia spirochaetes in the body of the patient. Borrelia is known to form semi-dormant spore-like forms in culture and within the cells of living mammalian hosts, and this may explain the persistance of Lyme symptoms when no spirochaetes are detectable in the blood. The relapses often observed in chronic Lyme patients who stop taking antibiotics after months or even years of treatment may be explicable in terms of 'hatching' of viable spirochaetes from this pool of spores.

The case for the possible clinical significance of spores in chronic Lyme disease has been boosted by a recently published study by Hodzic and colleagues, on mice deliberately infected with the Lyme spirochaete. Results indicated that following antibiotic treatment, mice remained infected with non-dividing but infectious spirochetes, particularly when antibiotic treatment was commenced during the chronic stage of infection. Discontinuation of antibiotics resulted in relapse and recurrence of Lyme disease, and feeding by ticks on these mice which were then transferred to feed on healthy mice led to the Borrelia spirochaete establishing itself within them.

Alternative therapies

A number of other alternative therapies have been suggested, though clinical trials have not been conducted. For example, the use of hyperbaric oxygen therapy (which is used conventionally to treat a number of other conditions), as an adjunct to antibiotics for Lyme has been discussed.[74] Though there are no published data from clinical trials to support its use, preliminary results using a mouse model suggest its effectiveness against B. burgdorferi both in vitro and in vivo.[75] Anecdotal clinical research has shown potential for the antifungal azole medications such as diflucan in the treatment of Lyme, but has yet to be repeated in a controlled study or postulated a developed hypothetical model for its use.[76]

Alternative medicine approaches include bee venom because it contains the peptide melittin, which has been shown to exert inhibitory effects on Lyme bacteria in vitro;[77] no clinical trials of this treatment have been carried out, however.

Prognosis

For early cases, prompt treatment is usually curative.[78] However, the severity and treatment of Lyme disease may be complicated due to late diagnosis, failure of antibiotic treatment, simultaneous infection with other tick-borne diseases including ehrlichiosis, babesiosis, and bartonella, and immune suppression in the patient.

A meta-analysis published in 2005 found that some patients with Lyme disease have fatigue, joint and/or muscle pain, and neurocognitive symptoms persisting for years despite antibiotic treatment.[79] Patients with late stage Lyme disease have been shown to experience a level of physical disability equivalent to that seen in congestive heart failure.[80]

In rare cases, Lyme disease can be fatal.[81][82][83][84]The first CDC recognized death from Lyme disease was Amanda Schmidt, age 11.[85]

Ecology

Urbanization and other anthropogenic factors can be implicated in the spread of the Lyme disease into the human population. In many areas, expansion of suburban neighborhoods has led to the gradual deforestation of surrounding wooded areas and increasing "border" contact between humans and tick-dense areas. Human expansion has also resulted in a gradual reduction of the predators that normally hunt deer as well as mice, chipmunks and other small rodents -- the primary reservoirs for Lyme disease. As a consequence of increased human contact with host and vector, the likelihood of transmission to Lyme residents has greatly increased.[86][87] Researchers are also investigating possible links between global warming and the spread of vector-borne diseases including Lyme disease.[88]

The deer tick (Ixodes scapularis, the primary vector in the northeastern U.S.) has a two-year life cycle, first progressing from larva to nymph, and then from nymph to adult. The tick feeds only once at each stage. In the fall, large acorn forests attract deer as well as mice, chipmunks and other small rodents infected with B. burgdorferi. During the following spring, the ticks lay their eggs. The rodent population then "booms." Tick eggs hatch into larvae, which feed on the rodents; thus the larvae acquire infection from the rodents. (Note: At this stage, it is proposed that tick infestation may be controlled using acaricides (miticide).

Adult ticks may also transmit disease to humans. After feeding, female adult ticks lay their eggs on the ground, and the cycle is complete. On the west coast, Lyme disease is spread by the western black-legged tick (Ixodes pacificus), which has a different life cycle.

The risk of acquiring Lyme disease does not depend on the existence of a local deer population, as is commonly assumed. New research suggests that eliminating deer from smaller areas (less than 2.5 ha or 6.2 acres) may in fact lead to an increase in tick density and the rise of "tick-borne disease hotspots".[89]

Epidemiology

Lyme disease is the most common tick-borne disease in North America and Europe, and one of the fastest-growing infectious diseases in the United States. Of cases reported to the United States Center for Disease Control (CDC), the ratio of Lyme disease infection is 7.9 cases for every 100,000 persons. In the ten states where Lyme disease is most common, the average was 31.6 cases for every 100,000 persons for the year 2005.[90]

Although Lyme disease has now been reported in 49 of 50 states in the U.S, about 99% of all reported cases are confined to just five geographic areas (New England, Mid-Atlantic, East-North Central, South Atlantic, and West North-Central). Charts and tables for Lyme disease statistics in the U.S. can be found at the CDC website.

The number of reported cases of the disease have been increasing, as are endemic regions in North America. For example, it had previously been thought that B. burgdorferi sensu lato couldn't be maintained in an enzootic cycle in California because it was assumed the large lizard population would dilute the prevalence of B. burgdorferi in local tick populations, but this has since been proven false as lizards are now known carriers of ticks in North America, Europe and North Africa. Indeed, the DNA of Borrelia has been detected in lizards, indicating that they can be infected.[91]

While B. burgdorferi is most associated with deer tick and the white tailed mouse, Borrelia afzelii is most frequently detected in rodent-feeding vector ticks, Borrelia garinii and Borrelia valaisiana appear to be associated with birds. Both rodents and birds are competent reservoir hosts for B. burgdorferi sensu stricto. The resistance of a genospecies of Lyme disease spirochetes to the bacteriolytic activities of the alternative complement pathway of various host species may determine its reservoir host association.

In Europe, cases of B. burgdorferi sensu lato infected ticks are found predominantly in Norway, Netherlands, Germany, France, Italy, Slovenia and Poland, but have been isolated in almost every country on the continent. Lyme disease statistics for Europe can be found at Eurosurveillance website.

B. burgdorferi sensu lato infested ticks are being found more frequently in Japan, as well as in Northwest China and far eastern Russia.[92][93] Borrelia has been isolated in Mongolia as well.[94]

In South America tick-borne disease recognition and occurrence is rising. Ticks carrying B. burgdorferi sensu lato, as well as canine and human tick-borne disease, have been reported widely in Brazil, but the subspecies of Borrelia has not yet been defined.[95] The first reported case of Lyme disease in Brazil was made in 1993 in Sao Paulo.[96] B. burgdorferi sensu stricto antigens in patients have been identified in Colombia and in Bolivia.

In Northern Africa B. burgdorferi sensu lato has been identified in Morocco, Algeria, Egypt and Tunisia.[97][98][99]

In Western and sub-Saharan Africa, tick-borne relapsing fever was first identified by the British physicians Joseph Dutton and John Todd in 1905. Borrelia in the manifestation of Lyme disease in this region is presently unknown but evidence indicates that Lyme disease may occur in humans in sub-Saharan Africa. The abundance of hosts and tick vectors would favor the establishment of Lyme infection in Africa.[100] In East Africa, two cases of Lyme disease have been reported in Kenya.[101]

In Australia there is no definitive evidence for the existence of B. burgdorferi or for any other tick-borne spirochete that may be responsible for a local syndrome being reported as Lyme disease.[102] Cases of neuroborreliosis have been documented in Australia but are often ascribed to travel to other continents. The existence of Lyme disease in Australia is controversial.

To date, data shows that Northern hemisphere temperate regions are most endemic for Lyme disease.[103][104]

Controversy

Main article: Lyme disease controversy

Most clinicians agree on the treatment of early Lyme disease infections.[105] There is, however, considerable disagreement regarding prevalence of the disease, diagnostic criteria, treatment of late-stage Lyme disease, and the likelihood of chronic, antibiotic-resistant infections. Some authorities contend that Lyme disease is relatively rare, easily diagnosed with available blood tests, and most often easily treated with two to four weeks of antibiotics,[106] while others propose that the disease is under-diagnosed, available blood tests are unreliable, and that extended antibiotic treatment is often necessary.[107][108][109]

The majority of public health agencies such as the U.S. Centers for Disease Control maintain the former position. Published studies involving non-randomized surveys of physicians in endemic areas found physicians evenly split in their views, with the majority recognizing seronegative Lyme disease, and roughly half prescribing extended courses of antibiotics for chronic Lyme disease, suggesting that there is much disagreement and confusion on this topic.[110][111]

The selection of leading Lyme researchers for such senior posts in biodefense and emerging infectious disease research has fueled conspiracy theories that suggest Lyme disease is clandestinely connected with biological warfare. Such lines of thought overlook the fact that the majority of infectious disease research is supported by the U.S. government via National Institutes of Health grants[112], and therefore the funding of Lyme disease research does not appear to be unusual.

In recent years, of a number of documents referring to the study of Lyme disease at facilities that also have BSL-4 (Biosafety Level 4) labs, the highest level of biocontainment which is reserved for highly infectious and deadly disease agents, has only served to stoke suspicion further. An example of one such document, which leads to this confusion, is a section on biocontainment in a 2003 letter from the director of a California Health Department concerning a bid for a biodefense grant, where possible research at a new lab is discussed.[113] The mixture of infectious disease work from BSL-1 to BSL-4 level agents at such facilities appears to be the source of confusion on this issue - the biosafety level that research on a pathogen is conducted at remains relatively constant.

Consistently, disagreement on the exact guidelines for diagnosis and treatment of Lyme disease has been a source of controversy and high emotions. In October 2006, further controversy erupted with the release of updated diagnosis and treatment guidelines from the Infectious Diseases Society of America (IDSA).[114] The new IDSA recommendations are more restrictive than prior IDSA treatment guidelines for Lyme,[115] and now require either an EM rash or positive laboratory tests for diagnosis; seronegative Lyme disease is no longer acknowledged (except incidentally in early Lyme disease). The authors of the guidelines maintain that chronic Lyme disease does not result from persistent infection, and therefore treatment beyond 2-4 weeks is not recommended, even in late stage cases. An opposing viewpoint has been expressed by the International Lyme and Associated Disease Society (ILADS), which proposes extended antibiotic treatment beyond four weeks for both early and late Lyme disease.[116] Hopefully future research will provide clarity on this issue.

Advancing immunology research

The role of T cells concomitant to Borrelia infection was first made in 1984,[117] and long term persistence of T cell lymphocyte responses to B. burgdorferi as an "immunological scar syndrome" was hypothesized in 1990.[118] The role of Th1 and interferon-gamma (IFN-gamma) in borrelia was first described in 1995.[119] The cytokine pattern of Lyme disease, and the role of Th1 with down regulation of interleukin-10 (IL-10) was first proposed in 1997.[120]

Inflammation

Further information: Innate immune system and Cell signaling networks

Recent studies in both acute and antibiotic refractory, or chronic, Lyme disease have shown a distinct pro-inflammatory immune process. This pro-inflammatory process is a cell-mediated immunity and results in Th1 upregulation. These studies have shown a significant decrease in cytokine output of (IL-10), an upregulation of Interleukin-6 (IL-6), Interleukin-12 (IL-12) and IFN-gamma and disregulation in TNF-alpha predominantly.[121]

These studies suggest that the host immune response to infection results in increased levels of IFN-gamma in the serum and lesions of Lyme disease patients that correlate with greater severity of disease. IFN-gamma alters gene expression by endothelia exposed to B. burgdorferi in a manner that promotes recruitment of T cells and suppresses that of neutrophils.

Studies also suggest suppressors of cytokine signaling (SOCS) proteins are induced by cytokines, and T cell receptor can down-regulate cytokine and T cell signaling in macrophages. It is hypothesized that SOCS are induced by IL-10 and B. burgdorferi and its lipoproteins in macrophages, and that SOCS may mediate the inhibition of IL-10 by concomitantly elicited cytokines. IL-10 is generally regarded as an anti-inflammatory cytokine, since it acts on a variety of cell types to suppress production of proinflammatory mediators.

Researchers are also beginning to identify microglia as a previously unappreciated source of inflammatory mediator production following infection with B. burgdorferi. Such production may play an important role during the development of cognitive disorders in Lyme neuroborreliosis. This effect is associated with induction of nuclear factor-kappa B (NF-KB) by Borrelia.[122][123]

Disregulated production of pro-inflammatory cytokines such as IL-6 and TNF-alpha can lead to neuronal damage in Borrelia infected patients.[124] IL-6 and TNF-Alpha cytokines produce fatigue and malaise, two of the more prominent symptoms experienced by patients with chronic Lyme disease.[125][126]IL-6 is also significantly indicated in cognitive impairment.[127]

Neuroendocrine

Further information: Signal transduction

A developing hypothesis is that the chronic secretion of stress hormones as a result of Borrelia infection may reduce the effect of neurotransmitters, or other receptors in the brain by cell-mediated pro-inflammatory pathways, thereby leading to the dysregulation of neurohormones, specifically glucocorticoids and catecholamines, the major stress hormones. [128][129]This process is mediated via the Hypothalamic-pituitary-adrenal axis. Additionally Tryptophan, a precursor to serotonin appears to be reduced within the CNS in a number of infectious diseases that affect the brain, including Lyme.[130] Researchers are investigating if this neurohormone secretion is the cause of neuro-psychiatric disorders developing in some patients with borreliosis.[131]

Antidepressants acting on serotonin, norepinephrine and dopamine receptors have been shown to be immunomodulatory and anti-inflammatory against pro-inflammatory cytokine processes, specifically on the regulation of IFN-gamma and IL-10, as well as TNF-alpha and IL-6 through a psycho-neuroimmunological process.[132] Antidepressants have also been shown to suppress Th1 upregulation.[133]These studies warrant investigation for antidepressants for use in a psycho-neuroimmunological approach for optimal pharmacotherapy of antibiotic refractory Lyme patients.[citation needed]

New developments

New research has also found that chronic Lyme patients have higher amounts of Borrelia-specific forkhead box P3 (FoxP3) than healthy controls, indicating that regulatory T cells might also play a role, by immunosuppression, in the development of chronic Lyme disease. FoxP3 are a specific marker of regulatory T cells.[134] The signaling pathway P38 mitogen-activated protein kinases (p38 MAP kinase) has also been identified as promoting expression of pro-inflammatory cytokines from Borrelia.[135]

The culmination of these new and ongoing immunological studies suggest this cell-mediated immune disruption in the Lyme patient amplifies the inflammatory process, often rendering it chronic and self-perpetuating, regardless of whether the Borrelia bacterium is still present in the host, or in the absence of the inciting pathogen in an autoimmune pattern.[136]. This interpretation must however be considered against the evidence (above) for persistence of the 'spore' form of Borrellia in human and animal hosts, and the tendency for relapses to occur after antibiotics are continued. It is possible that whereas some chronic Lyme patients retain actual populations of live spirochaetes, others have symptoms brought on only by an inflammatory or auto-immune reaction.

Researchers hope that this new developing understanding of the biomolecular basis and pathology of cell-mediated signaling events caused by B. burgdorferi infection will lead to a greater understanding of immune response and inflammation caused by Lyme disease and, hopefully, new treatment strategies for chronic antibiotic-resistant disease.

Lyme funding and treatment controversy

Some of the scientists involved in formulating what have become controversial Lyme diagnostic tests and treatment guidelines have been involved in both biodefense research, commercial vaccine, and diagnostic test development, which some view as a conflict of interest. [137] In response to these and other concerns expressed by the expanding national community of patients, Richard Blumenthal, the Attorney General of Connecticut has launched an investigation exploring possible conflicts of interest.

To date, federal research aimed at developing treatments for chronic Lyme disease is roughly $30 million, as contrasted to a $22 billion budget for military biodefense. Some scientists involved in Lyme treatment and diagnostic testing policy in the United States have a well publicized history in biodefense research, and many have recently received biodefense grants for BSL-3 and BSL-4 Labs where, critics contend, Lyme treatment research lacks transparency, accountability and focus on treatment research[138][139], though, it should be pointed out, that labs obtaining such grants are required to make their research findings publicly available via publication and focus their studies on issues pertinent to human health [140]. Most people familiar with the field contend that the new grants and centers stimulate research by bringing together experts in the field and providing a stable source of funding.[141]

Some examples of emerging infectious disease funding: In 2003, Lyme researcher Dr. Mark Klempner was appointed head of the new $1.6 billion biodefense high-containment facility at Boston University, the National Emerging Infectious Diseases Laboratories.[142][143] In 2004, Lyme researcher Dr. Jorge Benach,[144] was chosen as a recipient for a $3 million biodefense research grant, and in 2005, Lyme researcher Dr. Alan Barbour was placed in charge of a $40 million dollar new biodefense complex based at UC Irvine. [145]

History

The first record of a condition associated with Lyme disease dates to 1883 in Wrocław, Poland (then known as Breslau, Germany) where physician Alfred Buchwald described a degenerative skin disorder now known as acrodermatitis chronica atrophicans. In 1909, Arvid Afzelius presented research about an expanding, ring-like lesion he had observed. Afzelius published his work 12 years later and speculated that the rash came from the bite of an Ixodes tick, and that meningitic symptoms and signs occur in a number of cases; this rash is now known as erythema migrans (EM), the skin rash found in early stage Lyme disease.[146]

In the 1920s, French physicians Garin and Bujadoux described a patient with meningoencephalitis, painful sensory radiculitis, and erythema migrans following a tick bite, and they postulated the symptoms were due to a spirochetal infection. In the 1940s, German neurologist Alfred Bannwarth described several cases of chronic lymphocytic meningitis and polyradiculoneuritis, some of which were accompanied by erythematous skin lesions.

In 1948 spirochete-like structures were observed in skin specimens by Swedish dermatologist Carl Lennhoff.[147] In the 1950s, relations between tick bite, lymphocytoma, EM and Bannwarth's syndrome are seen throughout Europe leading to the use of penicillin for treatment.[148][149][150]

Interest in tick-borne infections in the U.S. began with the first report of tick-borne relapsing fever (Borrelia hermsii) in 1915, following the recognition of five human patients in Colorado.[151]

In 1970 a physician in Wisconsin named Rudolph Scrimenti reports the first case of EM in U.S. and treats it with penicillin based on European literature.[152]

The full syndrome now known as Lyme disease was not recognized until a cluster of cases originally thought to be juvenile rheumatoid arthritis was identified in three towns in southeastern Connecticut in 1975, including the towns Lyme and Old Lyme, which gave the disease its popular name.[153] This was investigated by Dr. David Snydman and Dr. Allen Steere of the Epidemic Intelligence Service, and by others from Yale University. The recognition that the patients in the United States had EM led to the recognition that "Lyme arthritis" was one manifestation of the same tick-borne condition known in Europe.[154]

Before 1976, elements of B. burgdorferi sensu lato infection were called or known as tickborne meningopolyneuritis, Garin-Bujadoux syndrome, Bannworth syndrome, Afzelius syndrome, Montauk Knee or sheep tick fever. Since 1976 the disease is most often referred to as Lyme disease,[155][156] Lyme borreliosis or simply borreliosis.

In 1980 Steere, et al, began to test antibiotic regimens in adult patients with Lyme disease[157] In 1982 a novel spirochete was cultured from the mid-gut of Ixodes ticks in Shelter Island, New York, and subsequently from patients with Lyme disease. The infecting agent was then identified by Jorge Benach at the State University of New York at Stony Brook, and soon after isolated by Willy Burgdorfer, a researcher at the National Institutes of Health, who specialized in the study of spirochete microorganisms such as Borrelia and Rickettsia. The spirochete was named Borrelia burgdorferi in his honor. Burgdorfer was the partner in the successful effort to culture the spirochete, along with Alan Barbour.

After identification B. burgdorferi as the causative agent of Lyme disease, antibiotics were selected for testing, guided by in vitro antibiotic sensitivities, including tetracycline antibiotics, amoxicillin, cefuroxime axetil, intravenous and intramuscular penicillin and intravenous ceftriaxone.[158][159] The mechanism of tick transmission was also the subject of much discussion. B. burgdorferi spirochetes were identified in tick saliva in 1987, confirming the hypothesis that transmission occurred via tick salivary glands.[160]

References

  1. ^ a b c d e f g h i j Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. pp. 434–7. ISBN 0838585299. {{cite book}}: |author= has generic name (help); |edition= has extra text (help)
  2. ^ Johnson RC (1996). "Borrelia". Baron's Medical Microbiology (Baron S et al, eds.) (4th ed. ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1. {{cite book}}: |edition= has extra text (help)
  3. ^ Johnson L (2005-02). "Lyme disease: two standards of care". International Lyme and Associated Diseases Society. Retrieved 2007-08-21. {{cite web}}: Check date values in: |date= (help)
  4. ^ Johnson L, Stricker R (2004). "Treatment of Lyme disease: a medicolegal assessment". Expert Rev Anti Infect Ther. 2 (4): 533–57. PMID 15482219.
  5. ^ CDC (2005-07-06). "Lyme Disease Erythema Migrans". Retrieved 2007-08-21.
  6. ^ Donta ST (2002). "Late and chronic Lyme disease". Med Clin North Am. 86 (2): 341–9, vii. PMID 11982305.
  7. ^ Edlow JA (2007-01-25). "Lyme disease". eMedicine. Retrieved 2007-08-21.
  8. ^ Steere AC, Sikand VK, Schoen RT, Nowakowski J (2003). "Asymptomatic infection with Borrelia burgdorferi". Clin. Infect. Dis. 37 (4): 528–32. PMID 12905137.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Fahrer H, Sauvain MJ, Zhioua E, Van Hoecke C, Gern LE (1998). "Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?". Eur. J. Epidemiol. 14 (2): 117–23. PMID 9556169.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ a b Ciesielski CA, Markowitz LE, Horsley R, Hightower AW, Russell H, Broome CV (1989). "Lyme disease surveillance in the United States, 1983-1986". Rev. Infect. Dis. 11 Suppl 6: S1435-41. PMID 2682955.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Chabria SB, Lawrason J (2007). "Altered mental status, an unusual manifestation of early disseminated Lyme disease: A case report". 1 (1): 62. doi:10.1186/1752-1947-1-62. PMID 17688693. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: unflagged free DOI (link)
  12. ^ Rosenhall U, Hanner P, Kaijser B (1988). "Borrelia infection and vertigo". Acta Otolaryngol. 106 (1–2): 111–6. PMID 3421091.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Moscatello AL, Worden DL, Nadelman RB, Wormser G, Lucente F (1991). "Otolaryngologic aspects of Lyme disease". Laryngoscope. 101 (6 Pt 1): 592–5. PMID 2041438.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ^ In rare cases, frank psychosis have been attributed to chronic Lyme disease effects, including mis-diagnoses of schizophrenia and bipolar disorder. Panic attack and anxiety can occur, also delusional behavior, including somataform delusions, sometimes accompanied by a depersonalization or derealization syndrome similar to what was seen in the past in the prodromal or early stages of general paresis.(Fallon BA, Nields JA (1994). "Lyme disease: a neuropsychiatric illness". The American journal of psychiatry. 151 (11): 1571–83. PMID 7943444.Hess A, Buchmann J, Zettl UK; et al. (1999). "Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenialike disorder". Biol. Psychiatry. 45 (6): 795. PMID 10188012. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link))
  15. ^ Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, Barbour AG (2004). "Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe" (PDF). Microbiology. 150 (Pt 6): 1741–55. PMID 15184561.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ from http://www.oregonlyme.org/ under topic "Borrelia Burgdorferi and other tick illnesses in Oregon"
  17. ^ "Lyme Disease Transmission". Lyme Disease. CDC. 2005-12-07. Retrieved 2007-08-21.
  18. ^ Wormser G, Masters E, Nowakowski J; et al. (2005). "Prospective clinical evaluation of patients from missouri and New York with erythema migrans-like skin lesions". Clin Infect Dis. 41 (7): 958–65. PMID 16142659. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  19. ^ Ledin KE; et al. (2005). "Borreliacidal activity of saliva of the tick Amblyomma americanum". Med Vet Entomol. 19 (1): 90–5. PMID 15752182. {{cite journal}}: Explicit use of et al. in: |author= (help)
  20. ^ Clark K (2004). "Borrelia species in host-seeking ticks and small mammals in northern Florida" (PDF). J Clin Microbiol. 42 (11): 5076–86. PMID 15528699.
  21. ^ Eisen L, Eisen RJ, Lane RS (2004). "The roles of birds, lizards, and rodents as hosts for the western black-legged tick Ixodes pacificus". J. Vector Ecol. 29 (2): 295–308. PMID 15709249.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Lane RS, Mun J, Eisen L, Eisen RJ (2006). "Refractoriness of the western fence lizard (Sceloporus occidentalis) to the Lyme disease group spirochete Borrelia bissettii". J. Parasitol. 92 (4): 691–6. PMID 16995383.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ^ Magnarelli L, Anderson J (1988). "Ticks and biting insects infected with the etiologic agent of Lyme disease, Borrelia burgdorferi" (PDF). J Clin Microbiol. 26 (8): 1482–6. PMID 3170711.
  24. ^ Luger S (1990). "Lyme disease transmitted by a biting fly". N Engl J Med. 322 (24): 1752. PMID 2342543.
  25. ^ Bach G (2001). "Recovery of Lyme spirochetes by PCR in semen samples of previously diagnosed Lyme disease patients.". 14th International Scientific Conference on Lyme Disease. {{cite conference}}: Unknown parameter |booktitle= ignored (|book-title= suggested) (help)
  26. ^ Schmidt B, Aberer E, Stockenhuber C; et al. (1995). "Detection of Borrelia burgdorferi DNA by polymerase chain reaction in the urine and breast milk of patients with Lyme borreliosis". Diagn Microbiol Infect Dis. 21 (3): 121–8. PMID 7648832. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  27. ^ Steere AC (2003-02-01). "Lyme Disease: Questions and Answers" (PDF). Massachusetts General Hospital / Harvard Medical School. Retrieved 2007-03-22.
  28. ^ Walsh CA, Mayer EW, Baxi LV (2007). "Lyme disease in pregnancy: case report and review of the literature". Obstetrical & gynecological survey. 62 (1): 41–50. doi:10.1097/01.ogx.0000251024.43400.9a. PMID 17176487.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. ^ Brown SL, Hansen SL, Langone JJ (1999). "Role of serology in the diagnosis of Lyme disease". JAMA. 282 (1): 62–6. PMID 10404913.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ^ Hofmann H (1996). "Lyme borreliosis--problems of serological diagnosis". Infection. 24 (6): 470–2. PMID 9007597.
  31. ^ "Lyme Disease (Borrelia burgdorferi): 1996 Case Definition". CDC Case Definitions for Infectious Conditions under Public Health Surveillance. 1996. Retrieved 2007-08-23.
  32. ^ "CDC Testimony before the Connecticut Department of Health and Attorney General's Office". CDC's Lyme Prevention and Control Activities. 2004-01-24. Retrieved 2007-08-23.
  33. ^ Pachner AR (1989). "Neurologic manifestations of Lyme disease, the new "great imitator"". Rev. Infect. Dis. 11 Suppl 6: S1482-6. PMID 2682960.
  34. ^ Engstrom SM, Shoop E, Johnson RC (1995). "Immunoblot interpretation criteria for serodiagnosis of early Lyme disease" (PDF). J Clin Microbiol. 33 (2): 419–27. PMID 7714202.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  35. ^ Sivak SL, Aguero-Rosenfeld ME, Nowakowski J, Nadelman RB, Wormser GP (1996). "Accuracy of IgM immunoblotting to confirm the clinical diagnosis of early Lyme disease". Arch Intern Med. 156 (18): 2105–9. PMID 8862103.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  36. ^ Goossens HA, Nohlmans MK, van den Bogaard AE (1999). "Epstein-Barr virus and cytomegalovirus infections cause false-positive results in IgM two-test protocol for early Lyme borreliosis". Infection. 27 (3): 231. PMID 10378140.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  37. ^ Strasfeld L, Romanzi L, Seder RH, Berardi VP (2005). "False-positive serological test results for Lyme disease in a patient with acute herpes simplex virus type 2 infection". Clin Infect Dis. 41 (12): 1826–7. PMID 16288417.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  38. ^ Molloy PJ, Persing DH, Berardi VP (2001). "False-positive results of PCR testing for Lyme disease". Clin. Infect. Dis. 33 (3): 412–3. PMID 11438915.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  39. ^ Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP (2005). "Diagnosis of lyme borreliosis". Clin. Microbiol. Rev. 18 (3): 484–509. doi:10.1128/CMR.18.3.484-509.2005. PMID 16020686.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  40. ^ Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC (1994). "Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis". N. Engl. J. Med. 330 (4): 229–34. PMID 8272083.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ^ Burdash N, Fernandes J (1991). "Lyme borreliosis: detecting the great imitator". The Journal of the American Osteopathic Association. 91 (6): 573–4, 577–8. PMID 1874654.
  42. ^ Coyle PK, Schutzer SE, Deng Z; et al. (1995). "Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease". Neurology. 45 (11): 2010–5. PMID 7501150. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  43. ^ Valentine-Thon E, Ilsemann K, Sandkamp M (2007). "A novel lymphocyte transformation test (LTT-MELISA) for Lyme borreliosis". Diagn. Microbiol. Infect. Dis. 57 (1): 27–34. doi:10.1016/j.diagmicrobio.2006.06.008. PMID 16876371.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  44. ^ Eisendle K, Grabner T, Zelger B (2007). "Focus floating microscopy: "gold standard" for cutaneous borreliosis?". Am. J. Clin. Pathol. 127 (2): 213–22. doi:10.1309/3369XXFPEQUNEP5C. PMID 17210530.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  45. ^ Cadavid D (2006). "The mammalian host response to borrelia infection". Wien. Klin. Wochenschr. 118 (21–22): 653–8. doi:10.1007/s00508-006-0692-0. PMID 17160603.
  46. ^ Sumiya H, Kobayashi K, Mizukoshi C; et al. (1997). "Brain perfusion SPECT in Lyme neuroborreliosis". J. Nucl. Med. 38 (7): 1120–2. PMID 9225802. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  47. ^ Logigian EL, Johnson KA, Kijewski MF; et al. (1997). "Reversible cerebral hypoperfusion in Lyme encephalopathy". Neurology. 49 (6): 1661–70. PMID 9409364. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  48. ^ Fallon BA, Das S, Plutchok JJ, Tager F, Liegner K, Van Heertum R (1997). "Functional brain imaging and neuropsychological testing in Lyme disease". Clin. Infect. Dis. 25 Suppl 1: S57-63. PMID 9233666.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  49. ^ Fallon, BA (2000). Review of Lyme Neuroborreliosis. 3th International Scientific Conference on Lyme Disease and other Tick-borne Disorders.
  50. ^ Kalina P, Decker A, Kornel E, Halperin JJ (2005). "Lyme disease of the brainstem". Neuroradiology. 47 (12): 903–7. doi:10.1007/s00234-005-1440-2. PMID 16158278.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  51. ^ Fallon BA, Keilp J, Prohovnik I, Heertum RV, Mann JJ (2003). "Regional cerebral blood flow and cognitive deficits in chronic lyme disease". The Journal of neuropsychiatry and clinical neurosciences. 15 (3): 326–32. PMID 12928508.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Piesman J, Dolan MC (2002). "Protection against lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae)". J Med Entomol. 39 (3): 509–12. PMID 12061448.
  53. ^ Rand PW, Lubelczyk C, Holman MS, Lacombe EH, Smith RP (2004). "Abundance of Ixodes scapularis (Acari: Ixodidae) after the complete removal of deer from an isolated offshore island, endemic for Lyme Disease". J. Med. Entomol. 41 (4): 779–84. PMID 15311475.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  54. ^ Figure 2. p.4. DEP Wildlife Division: Managing Urban Deer in Connecticut 2nd edition June 2007
  55. ^ Stafford KC (2004). "Tick Management Handbook" (PDF). Connecticut Agricultural Experiment Station and Connecticut Department of Public Health. pp. p. 46. Retrieved 2007-08-21. {{cite web}}: |pages= has extra text (help)
  56. ^ Safety/Efficacy concerns re: Lyme vaccine: LYMErix Controversy LymeInfo.net
  57. ^ Willett TA, Meyer AL, Brown EL, Huber BT (2004). "An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope". Proc. Natl. Acad. Sci. U.S.A. 101 (5): 1303–8. doi:10.1073/pnas.0305680101. PMID 14742868.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  58. ^ Earnhart CG, Marconi RT (2007). "OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine". Clin. Vaccine Immunol. 14 (5): 628–34. doi:10.1128/CVI.00409-06. PMID 17360854.
  59. ^ Pozsgay V, Kubler-Kielb J (2007). "Synthesis of an experimental glycolipoprotein vaccine against Lyme disease". Carbohydr. Res. 342 (3–4): 621–6. doi:10.1016/j.carres.2006.11.014. PMID 17182019.
  60. ^ Zeller JL, Burke AE, Glass RM (2007). "JAMA patient page. Lyme disease". JAMA. 297 (23): 2664. doi:10.1001/jama.297.23.2664. PMID 17579234.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  61. ^ Piesman J, Dolan MC (2002). "Protection against lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae)". J Med Entomol. 39 (3): 509–12. PMID 12061448.
  62. ^ Muellegger RR, Zoechling N, Soyer HP; et al. (1995). "No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment". Archives of dermatology. 131 (6): 678–82. PMID 7778919. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  63. ^ Liegner KB, Shapiro JR, Ramsay D, Halperin AJ, Hogrefe W, Kong L (1993). "Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting Borrelia burgdorferi infection". J. Am. Acad. Dermatol. 28 (2 Pt 2): 312–4. PMID 8436647.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  64. ^ International Lyme and Associated Diseases Society (ILADS)
  65. ^ Infectious Diseases Society of America
  66. ^ Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, Krupp L, Gronseth G, Bever CT (2007). "Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 69 (1): 91–102. doi:10.1212/01.wnl.0000265517.66976.28. PMID 17522387.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  67. ^ Oksi J, Nikoskelainen J, Hiekkanen H; et al. (2007). "Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study". Eur. J. Clin. Microbiol. Infect. Dis. 26 (8): 571–81. doi:10.1007/s10096-007-0340-2. PMID 17587070. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  68. ^ Oksi J, Marjamäki M, Nikoskelainen J, Viljanen MK (1999). "Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis". Ann. Med. 31 (3): 225–32. PMID 10442678.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  69. ^ Hartiala P, Hytönen J, Pelkonen J; et al. (2007). "Transcriptional response of human dendritic cells to Borrelia garinii--defective CD38 and CCR7 expression detected". J. Leukoc. Biol. 82 (1): 33–43. doi:10.1189/jlb.1106709. PMID 17440035. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  70. ^ Massarotti EM (2002). "Lyme arthritis". Med. Clin. North Am. 86 (2): 297–309. PMID 11982303.
  71. ^ Puéchal X (2007). "Non antibiotic treatments of Lyme borreliosis". Med Mal Infect. [Epub ahead of print]. doi:10.1016/j.medmal.2006.01.021. PMID 17376627.
  72. ^ Weissenbacher S, Ring J, Hofmann H (2005). "Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study". Dermatology (Basel). 211 (2): 123–7. doi:10.1159/000086441. PMID 16088158.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  73. ^ Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M (2004). "Clinical potential of minocycline for neurodegenerative disorders". Neurobiol. Dis. 17 (3): 359–66. doi:10.1016/j.nbd.2004.07.012. PMID 15571972.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  74. ^ Taylor R, Simpson I (2005). "Review of treatment options for Lyme borreliosis". J Chemother. 17 Suppl 2: 3–16. PMID 16315580.
  75. ^ Pavia C (2003). "Current and novel therapies for Lyme disease". Expert Opin Investig Drugs. 12 (6): 1003–16. PMID 12783604.
  76. ^ Schardt FW (2004). "Clinical effects of fluconazole in patients with neuroborreliosis". Eur. J. Med. Res. 9 (7): 334–6. PMID 15337633.
  77. ^ Lubke LL, Garon CF (1997). "The antimicrobial agent melittin exhibits powerful in vitro inhibitory effects on the Lyme disease spirochete". Clin. Infect. Dis. 25 Suppl 1: S48-51. PMID 9233664.
  78. ^ Krause PJ, Foley DT, Burke GS, Christianson D, Closter L, Spielman A (2006). "Reinfection and relapse in early Lyme disease". Am. J. Trop. Med. Hyg. 75 (6): 1090–4. PMID 17172372.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  79. ^ Cairns V, Godwin J (2005). "Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms". Int J Epidemiol. 34 (6): 1340–5. PMID 16040645.
  80. ^ Klempner MS, Hu LT, Evans J; et al. (2001). "Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease". N Engl J Med. 345 (2): 85–92. PMID 11450676. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  81. ^ Kirsch M, Ruben FL, Steere AC, Duray PH, Norden CW, Winkelstein A (1988). "Fatal adult respiratory distress syndrome in a patient with Lyme disease". JAMA. 259 (18): 2737–9. PMID 3357244.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  82. ^ Oksi J, Kalimo H, Marttila RJ; et al. (1996). "Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature". Brain. 119 (Pt 6): 2143–54. PMID 9010017. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  83. ^ Waniek C, Prohovnik I, Kaufman MA, Dwork AJ (1995). "Rapidly progressive frontal-type dementia associated with Lyme disease". J Neuropsychiatry Clin Neurosci. 7 (3): 345–7. PMID 7580195.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  84. ^ Cary NR, Fox B, Wright DJ, Cutler SJ, Shapiro LM, Grace AA (1990). "Fatal Lyme carditis and endodermal heterotopia of the atrioventricular node". Postgrad Med J. 66 (772): 134–6. PMID 2349186.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  85. ^ "First Lyme Disease Death Told". Los Angeles Times. 1990-09-26.
  86. ^ LoGiudice K, Ostfeld R, Schmidt K, Keesing F (2003). "The ecology of infectious disease: effects of host diversity and community composition on Lyme disease risk". Proc Natl Acad Sci U S A. 100 (2): 567–71. PMID 12525705.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  87. ^ Patz J, Daszak P, Tabor G; et al. (2004). "Unhealthy landscapes: Policy recommendations on land use change and infectious disease emergence". Environ Health Perspect. 112 (10): 1092–8. PMID 15238283. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  88. ^ Khasnis AA, Nettleman MD (2005). "Global warming and infectious disease". Arch. Med. Res. 36 (6): 689–96. doi:10.1016/j.arcmed.2005.03.041. PMID 16216650.
  89. ^ Perkins SE, Cattadori IM, Tagliapietra V, Rizzoli AP, Hudson PJ (2006). "Localized deer absence leads to tick amplification". Ecology. 87 (8): 1981–6. PMID 16937637.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  90. ^ CDC (2006-10-02). "Reported Cases of Lyme Disease by Year, United States, 1991-2005". Retrieved 2007-08-20.
  91. ^ Swanson KI, Norris DE (2007). "Detection of Borrelia burgdorferi DNA in lizards from Southern Maryland". Vector Borne Zoonotic Dis. 7 (1): 42–9. doi:10.1089/vbz.2006.0548. PMID 17417956.
  92. ^ Li M, Masuzawa T, Takada N; et al. (1998). "Lyme disease Borrelia species in northeastern China resemble those isolated from far eastern Russia and Japan". Appl. Environ. Microbiol. 64 (7): 2705–9. PMID 9647853. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  93. ^ Masuzawa T (2004). "Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia". Jpn. J. Infect. Dis. 57 (6): 229–35. PMID 15623946.
  94. ^ Walder G, Lkhamsuren E, Shagdar A; et al. (2006). "Serological evidence for tick-borne encephalitis, borreliosis, and human granulocytic anaplasmosis in Mongolia". Int. J. Med. Microbiol. 296 Suppl 40: 69–75. doi:10.1016/j.ijmm.2006.01.031. PMID 16524782. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  95. ^ Mantovani E, Costa IP, Gauditano G, Bonoldi VL, Higuchi ML, Yoshinari NH (2007). "Description of Lyme disease-like syndrome in Brazil. Is it a new tick borne disease or Lyme disease variation?". Braz. J. Med. Biol. Res. 40 (4): 443–56. PMID 17401487.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  96. ^ Yoshinari NH, Oyafuso LK, Monteiro FG; et al. (1993). "Lyme disease. Report of a case observed in Brazil". Revista do Hospital das Clínicas (in Portuguese). 48 (4): 170–4. PMID 8284588. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  97. ^ Bouattour A, Ghorbel A, Chabchoub A, Postic D (2004). "Lyme borreliosis situation in North Africa". Archives de l'Institut Pasteur de Tunis (in French). 81 (1–4): 13–20. PMID 16929760.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  98. ^ Dsouli N, Younsi-Kabachii H, Postic D; et al. (2006). "Reservoir role of lizard Psammodromus algirus in transmission cycle of Borrelia burgdorferi sensu lato (Spirochaetaceae) in Tunisia". J. Med. Entomol. 43 (4): 737–42. PMID 16892633. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  99. ^ Helmy N (2000). "Seasonal abundance of Ornithodoros (O.) savignyi and prevalence of infection with Borrelia spirochetes in Egypt". Journal of the Egyptian Society of Parasitology. 30 (2): 607–19. PMID 10946521.
  100. ^ Fivaz BH, Petney TN (1989). "Lyme disease--a new disease in southern Africa?". Journal of the South African Veterinary Association. 60 (3): 155–8. PMID 2699499.
  101. ^ Jowi JO, Gathua SN (2005). "Lyme disease: report of two cases". East African medical journal. 82 (5): 267–9. PMID 16119758.
  102. ^ Piesman J, Stone BF (1991). "Vector competence of the Australian paralysis tick, Ixodes holocyclus, for the Lyme disease spirochete Borrelia burgdorferi". Int. J. Parasitol. 21 (1): 109–11. PMID 2040556.
  103. ^ Grubhoffer L, Golovchenko M, Vancová M, Zacharovová-Slavícková K, Rudenko N, Oliver JH (2005). "Lyme borreliosis: insights into tick-/host-borrelia relations". Folia Parasitol. 52 (4): 279–94. PMID 16405291.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  104. ^ Higgins R (2004). "Emerging or re-emerging bacterial zoonotic diseases: bartonellosis, leptospirosis, Lyme borreliosis, plague". Rev. - Off. Int. Epizoot. 23 (2): 569–81. PMID 15702720.
  105. ^ Murray T, Feder H (2001). "Management of tick bites and early Lyme disease: a survey of Connecticut physicians". Pediatrics. 108 (6): 1367–70. PMID 11731662.
  106. ^ Wormser G (2006). "Clinical practice. Early Lyme disease". N Engl J Med. 354 (26): 2794–801. PMID 16807416.
  107. ^ Stricker RB, Lautin A, Burrascano JJ (2006). "Lyme Disease: The Quest for Magic Bullets". Chemotherapy. 52 (2): 53–59. PMID 16498239.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  108. ^ Phillips SE, Harris NS, Horowitz R, Johnson L, Stricker RB (2005). "Lyme disease: scratching the surface". Lancet. 366 (9499): 1771. PMID 16298211.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  109. ^ Phillips S, Bransfield R, Sherr V, Brand S, Smith H, Dickson K, and Stricker R (2003). "Evaluation of antibiotic treatment in patients with persistent symptoms of Lyme disease: an ILADS position paper" (PDF). International Lyme and Associated Diseases Society. Retrieved 2006-03-15.{{cite web}}: CS1 maint: multiple names: authors list (link)
  110. ^ Ziska MH, Donta ST, Demarest FC (1996). "Physician preferences in the diagnosis and treatment of Lyme disease in the United States". Infection. 24 (2): 182–6. PMID 8740119.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  111. ^ Eppes SC, Klein JD, Caputo GM, Rose CD (1994). "Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area". Clin Pediatr (Phila). 33 (3): 130–4. PMID 8194286.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  112. ^ "All About Grants" Tutorials - NIAID Research Funding
  113. ^ http://www.yolocounty.org/org/BOS/agendas/2003/012803/46.pdf Letter from head of Yolo County health department, California
  114. ^ "New Lyme Disease Guidelines Spark Showdown". U.S. Department of Health and Human Services. 2006-11-09. Retrieved 2007-08-21.
  115. ^ Wormser G, Dattwyler R, Shapiro E; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. PMID 17029130. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  116. ^ "Treatment guidelines". International Lyme and Associated Disease Society. 2007. Retrieved 2007-08-21.
  117. ^ Newman K, Johnson RC (1984). "T-cell-independent elimination of Borrelia turicatae". Infect. Immun. 45 (3): 572–6. PMID 6332075.
  118. ^ Krüger H, Pulz M, Martin R, Sticht-Groh V (1990). "Long-term persistence of specific T- and B-lymphocyte responses to Borrelia burgdorferi following untreated neuroborreliosis". Infection. 18 (5): 263–7. PMID 2276818.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  119. ^ Forsberg P, Ernerudh J, Ekerfelt C, Roberg M, Vrethem M, Bergström S (1995). "The outer surface proteins of Lyme disease borrelia spirochetes stimulate T cells to secrete interferon-gamma (IFN-gamma): diagnostic and pathogenic implications". Clin. Exp. Immunol. 101 (3): 453–60. PMID 7664493.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  120. ^ Yin Z, Braun J, Neure L; et al. (1997). "T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines". Arthritis Rheum. 40 (1): 69–79. PMID 9008602. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  121. ^ Shin JJ, Glickstein LJ, Steere AC (2007). "High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis". Arthritis Rheum. 56 (4): 1325–35. doi:10.1002/art.22441. PMID 17393419.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  122. ^ Rasley A, Anguita J, Marriott I (2002). "Borrelia burgdorferi induces inflammatory mediator production by murine microglia". J. Neuroimmunol. 130 (1–2): 22–31. PMID 12225885.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  123. ^ Rasley A, Tranguch SL, Rati DM, Marriott I (2006). "Murine glia express the immunosuppressive cytokine, interleukin-10, following exposure to Borrelia burgdorferi or Neisseria meningitidis". Glia. 53 (6): 583–92. doi:10.1002/glia.20314. PMID 16419089.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  124. ^ Ramesh G, Philipp MT (2005). "Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins". Neurosci. Lett. 384 (1–2): 112–6. doi:10.1016/j.neulet.2005.04.069. PMID 15893422.
  125. ^ "Welcome to Lyme Disease Research Studies". Retrieved 2007-08-23.
  126. ^ Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998). "The pathophysiologic roles of interleukin-6 in human disease". Ann. Intern. Med. 128 (2): 127–37. PMID 9441573.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  127. ^ Wright CB, Sacco RL, Rundek TR; et al. (2006). "Interleukin-6 is associated with cognitive function: the Northern Manhattan Study". 15 (1): 34–38. doi:10.1016/j.jstrokecerebrovasdis.2005.08.009. PMID 16501663. {{cite journal}}: Cite journal requires |journal= (help); Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  128. ^ Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP (2005). "Cytokine dysregulation, inflammation and well-being". Neuroimmunomodulation. 12 (5): 255–69. doi:10.1159/000087104. PMID 16166805.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  129. ^ Calcagni E, Elenkov I (2006). "Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases". Ann. N. Y. Acad. Sci. 1069: 62–76. doi:10.1196/annals.1351.006. PMID 16855135.
  130. ^ Gasse T, Murr C, Meyersbach P; et al. (1994). "Neopterin production and tryptophan degradation in acute Lyme neuroborreliosis versus late Lyme encephalopathy". European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies. 32 (9): 685–9. PMID 7865624. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  131. ^ Zajkowska J, Grygorczuk S, Kondrusik M, Pancewicz S, Hermanowska-Szpakowicz T (2006). "New aspects of pathogenesis of Lyme borreliosis". Przegla̧d epidemiologiczny (in Polish). 60 Suppl 1: 167–70. PMID 16909797.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  132. ^ Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M (2001). "Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio". Journal of clinical psychopharmacology. 21 (2): 199–206. PMID 11270917.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  133. ^ Diamond M, Kelly JP, Connor TJ (2006). "Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 16 (7): 481–90. doi:10.1016/j.euroneuro.2005.11.011. PMID 16388933.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  134. ^ Jarefors S, Janefjord CK, Forsberg P, Jenmalm MC, Ekerfelt C (2007). "Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals". Clin. Exp. Immunol. 147 (1): 18–27. doi:10.1111/j.1365-2249.2006.03245.x. PMID 17177959.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  135. ^ Ramesh G, Philipp MT (2005). "Pathogenesis of Lyme neuroborreliosis: mitogen-activated protein kinases Erk1, Erk2, and p38 in the response of astrocytes to Borrelia burgdorferi lipoproteins". Neurosci. Lett. 384 (1–2): 112–6. doi:10.1016/j.neulet.2005.04.069. PMID 15893422.
  136. ^ Singh SK, Girschick HJ (2006). "Toll-like receptors in Borrelia burgdorferi-induced inflammation". Clin. Microbiol. Infect. 12 (8): 705–17. doi:10.1111/j.1469-0691.2006.01440.x. PMID 16842565.
  137. ^ Conflicts of Interest in Lyme Disease: Treatment, Laboratory Testing, and Vaccination, Lyme Disease Association Inc., 2001
  138. ^ Biocontainment lab planned at Primate Center, PONTCHARTRAIN NEWSPAPERS COVINGTON, St. Tammany News, www.newsbanner.com Dec. 13, 2004
  139. ^ "Lyme Disease is Biowarfare Issue" by Elena Cooke, published/discussed by Dave Emory, WFMU Talk Show Host, 2007 http://ftrsupplemental.blogspot.com/2007/02/history-of-lyme-disease-as-bioweapon.html
  140. ^ Grants Policy & Guidance
  141. ^ UCI Medical Centre, June 1, 2005
  142. ^ Washington Post January 22, 2005
  143. ^ BUMC Faculty Webpage
  144. ^ NYStar News Publication of the New York State Office of Science, Technology and Academic Research, August 2004
  145. ^ UCI Medical Centre, June 1, 2005
  146. ^ Lipschütz B (1931). "Zur Kenntnis der "Erythema chronicum migrans"". Acta dermato-venereologica (in German). 12: 100–102.
  147. ^ Lenhoff C (1948). "Spirochetes in aetiologically obscure diseases". Acta Dermato-Venreol. 28: 295–324.
  148. ^ Bianchi GE (1950). "Penicillin therapy of lymphocytoma". Dermatologica. 100 (4–6): 270–3. PMID 15421023.
  149. ^ Hollstrom E (1951). "Successful treatment of erythema migrans Afzelius". Acta Derm. Venereol. 31 (2): 235–43. PMID 14829185.
  150. ^ Paschoud JM (1954). "Lymphocytoma after tick bite". Dermatologica (in German). 108 (4–6): 435–7. PMID 13190934.
  151. ^ Meador CN (1915). "Five cases of relapsing fever originating in Colorado, with positive blood findings in two". Colorado Medicine. 12: 365–9.
  152. ^ Scrimenti RJ (1970). "Erythema chronicum migrans". Archives of dermatology. 102 (1): 104–5. PMID 5497158.
  153. ^ Steere AC (2006). "Lyme borreliosis in 2005, 30 years after initial observations in Lyme Connecticut". Wien. Klin. Wochenschr. 118 (21–22): 625–33. doi:10.1007/s00508-006-0687-x. PMID 17160599.
  154. ^ Sternbach G, Dibble C (1996). "Willy Burgdorfer: Lyme disease". J Emerg Med. 14 (5): 631–4. PMID 8933327.
  155. ^ Mast WE, Burrows WM (1976). "Erythema chronicum migrans and "Lyme arthritis"". JAMA. 236 (21): 2392. PMID 989847.
  156. ^ Steere AC, Malawista SE, Snydman DR; et al. (1977). "Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities". Arthritis Rheum. 20 (1): 7–17. PMID 836338. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  157. ^ Steere AC, Hutchinson GJ, Rahn DW; et al. (1983). "Treatment of the early manifestations of Lyme disease". Ann. Intern. Med. 99 (1): 22–6. PMID 6407378. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  158. ^ Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ (1988). "New chemotherapeutic approaches in the treatment of Lyme borreliosis". Ann. N. Y. Acad. Sci. 539: 352–61. PMID 3056203.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  159. ^ Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ (1990). "Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis". Lancet. 336 (8728): 1404–6. PMID 1978873.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  160. ^ Ribeiro JM, Mather TN, Piesman J, Spielman A (1987). "Dissemination and salivary delivery of Lyme disease spirochetes in vector ticks (Acari: Ixodidae)". J. Med. Entomol. 24 (2): 201–5. PMID 3585913.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Jason Scott Smith, originally from Nantucket, MA was the first little boy treated for Lyme disease at Children's Hospital in Boston, MA. And they didn't know what the fuck was wrong with him...and they still don't till this day.

Wikispecies has information related to Borrelia.
General
Images
Professional societies, foundations, advocacy
Other


Template:FA link

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lyme_disease&oldid=206478420"